Night time asthma score Mean difference · Preschool children (<6 years)
1 finding from 1 review
Adverse events · Preschool children (<6 years)
Intermittent ICS showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Exacerbations requiring oral corticosteroids ‐ adults · School‐aged children and adults
Intermittent ICS showed no clear difference in exacerbations requiring oral corticosteroids ‐ adults compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · School‐aged children and adults
Intermittent ICS showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Day time asthma score Mean difference · School‐aged children and adults
1 finding from 1 review
Night time asthma score Mean difference · School‐aged children and adults
1 finding from 1 review
Adverse events · School‐aged children and adults
Intermittent ICS showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Mean exacerbations requiring a course of oral corticosteroids · Preschool children (<6 years)
Intermittent ICS probably leads to lower exacerbations requiring oral corticosteroids compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · Preschool children (<6 years)
Intermittent ICS showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Hospital admissions · Preschool children (<6 years)
It is very uncertain whether intermittent ICS changes hospitalisations compared with placebo (very low certainty).
1 finding from 1 review
Rate of exacerbations requiring systemic corticosteroids · adults with asthma well controlled on LABA and ICS
Stopping LABA showed no clear difference in exacerbation: systemic corticosteroids 17 weeks compared with continuing use of LABA+ICS (moderate certainty).
1 finding from 1 review
Asthma control · adults with asthma well controlled on LABA and ICS
1 finding from 1 review
Serious adverse events 17 weeks · adults with asthma well controlled on LABA and ICS
Stopping LABA showed no clear difference in serious adverse events 17 weeks compared with continuing use of LABA+ICS (moderate certainty).
1 finding from 1 review
Asthma‐related quality of life (MCID) · adults with asthma well controlled on LABA and ICS
1 finding from 1 review
Exacerbation: hospital 17 weeks · adults with asthma well controlled on LABA and ICS
1 finding from 1 review
Adverse events (all) · adults with asthma well controlled on LABA and ICS
Stopping LABA showed no clear difference in adverse events (all) compared with continuing use of LABA+ICS (moderate certainty).
1 finding from 1 review
Withdrawal (all‐cause) · adults with asthma well controlled on LABA and ICS
Stopping LABA probably leads to higher withdrawal (all) compared with continuing use of LABA+ICS (moderate certainty).
1 finding from 1 review
Exacerbations (OCS) · adults with asthma not well controlled on ICS
LAMA add‐on leads to lower exacerbations requiring oral corticosteroids (OCS) compared with ICS alone (high certainty).
1 finding from 1 review
Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · adults with asthma not well controlled on ICS
1 finding from 1 review
All‐cause serious adverse events 24 weeks · adults with asthma not well controlled on ICS
LAMA add‐on showed no clear difference in all‐cause serious adverse events 24 weeks compared with ICS alone (low certainty).
1 finding from 1 review